TABLE 1.
Age at diagnosis, median (range) | 69 (31‐88) |
Gender, N (%) | |
Female | 10 (41.7) |
Male | 14 (58.3) |
Race/Ethnicity, N (%) | |
Hispanic | 11 (41.8) |
White | 6 (25.0) |
Asian | 4 (16.7) |
Black | 3 (12.5) |
Hematologic malignancy, N (%) | 14 (58.3) |
Non‐Hodgkin lymphoma | 5 (20.8) |
Multiple myeloma | 4 (16.7) |
Acute lymphoblastic leukemia | 2 (8.3) |
Hodgkin lymphoma | 1 (4.2) |
Myelofibrosis | 1 (4.2) |
Chronic lymphocytic leukemia | 1 (4.2) |
Solid malignancy, N (%) | 10 (41.7) |
Colorectal | 2 (8.3) |
Breast | 2 (8.3) |
Endometrial | 2 (8.3) |
Prostate | 1 (4.2) |
Lung | 1 (4.2) |
Ovarian | 1 (4.2) |
Laryngeal | 1 (4.2) |
Stage of solid tumor, N (%) | |
I | 3 (30.0) |
II | 3 (30.0) |
III | 4 (40.0) |
Active disease, N (%) | 17 (70.8) |
Receiving cancer‐directed treatment at time of convalescent plasma, N (%) | 11 (45.8) |
Targeted therapy | 9 (37.5) |
Systemic chemotherapy | 6 (25.0) |
Radiation therapy | 1 (4.2) |
Immunomodulator | 2 (8.3) |
Intrathecal chemotherapy | 1 (4.2) |
Time from cancer diagnosis to convalescent plasma in months, median (range) | 42.1 (2.3‐274.9) |